Vor Biopharma Inc.

Vor Biopharma Inc.

VOR·NASDAQ

$14.53

+8.0%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$99.55M
EPS-70.5000
P/E Ratio-0.21
Earnings Date08/11/2026

vor

Other Current Assets

Last Annual Value

2.90M

3-Year CAGR

7%

5-Year CAGR

96%

10-Year CAGR

%

Vor Biopharma Inc.

Vor Biopharma Inc. Competitors Analysis of Other Current Assets

VOR · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.90M
82.7%6.7%N/A 
2.81M
157.4%99.5%8.8%
1.63M
-26.9%N/AN/A
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
6.06M
1.8%59.9%17.2%
6.23M
-17.5%-10.4%7.4%
1.51M
99.1%51.1%26.0%
535.00K
-19.1%N/AN/A
9.10M
14.2%N/A9.4%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
3.93M
-1.2%22.8%N/A
994.00K
-7.9%N/AN/A
2.69M
317.5%139.7%-8.2%
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR · NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.525, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

Intrinsic Value
Current Price: $14.525